Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.56 +5.13%

+$0.08 today

Market cap
$381.13M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 1.27M

Average 0.65M

ALEC Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Alector, Inc.NASDAQ: ALEC

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $24.18M rose 64.2% year over year, ahead of the -17.6% change in trailing-twelve-month operating expenses. Sequentially, it fell 47.2% from the prior quarter. Over 3 fiscal years it compounded at -16.6% a year.

Context

  • Operating expenses amounted to 746.9% of revenue in FY2025, up 687.6 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +64.2% holds above the trailing-twelve-month pace of -17.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.18M-47.2% QoQ
Last fiscal yearDec 2025
$157.19M+163.7% YoY
LTMMar 2026
$125.25M-17.6% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+64.2%——
1 year+163.7%——
3-year CAGR-16.6%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
157.19M USD
Year-over-year change
+163.7%
4-year CAGR
+30.0%

Operating Expenses vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.6% is the 7th highest of 9, against a peer median of -10.6%.
  • Operating expenses amounts to 680.1% of revenue for ALEC, versus a peer median of 1100.2%.
ALEC Competitors
Operating Expenses for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$373.48M USD+210.2%+63.9%—
ALECAlector, Inc.LTM Mar 2026$125.25M USD-17.6%-16.6%680.1%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$114.57M USD-9.5%+39.9%—
NKTXNkarta, Inc.LTM Mar 2026$113.97M USD-13.7%-2.0%—
FATEFate Therapeutics, Inc.LTM Mar 2026$113.16M USD-11.7%-28.7%1791.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$89.69M USD+109.1%+36.8%—
PEPGPepGen Inc.LTM Mar 2026$79.52M USD-27.0%+10.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 63.08M CHF+100.0%-11.3%—
IRDOpus Genetics, Inc.LTM Mar 2026$48.98M USD-30.2%+34.7%408.8%
Peer median (excluding ALEC) —-10.6%+22.6%1100.2%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue207.09M133.62M97.06M100.56M21.05M
Cost of Revenue189.41M08.85M185.94M9.66M
Gross Profit17.68M133.62M88.21M(85.38M)11.38M
Gross Margin8.5%100.0%90.9%-84.9%54.1%
Research & Development189.41M210.42M192.12M209.24M123.07M
Selling, General & Admin55.04M61.03M56.69M57.41M53.99M
Operating Expenses55.04M271.45M239.95M59.62M157.19M
Depreciation & Amortization8.32M8.47M8.85M8.84M9.66M
EBITDA(28.01M)(121.58M)(116.33M)(110.08M)(133.1M)
EBITDA Margin-13.5%-91.0%-119.9%-109.5%-632.5%
Operating Income(37.36M)(137.83M)(151.74M)(145M)(145.81M)
Operating Margin-18.0%-103.2%-156.3%-144.2%-692.8%
Interest Income00000
Interest Expense00000
Other Income / Expenses1.03M7.78M26.56M26.08M3.05M
Income Before Tax(36.33M)(130.06M)(125.18M)(118.92M)(142.76M)
Pre-Tax Margin-17.5%-97.3%-129.0%-118.3%-678.4%
Income Tax Expense03.25M5.21M128K168K
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (Basic)(0.45)(1.62)(1.56)(1.23)(1.39)
EPS (Diluted)(0.45)(1.62)(1.56)(1.23)(1.39)
Weighted Avg Shares80.42M82.47M83.73M96.59M103M
Weighted Avg Shares (Diluted)80.42M82.47M83.73M96.59M103M

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.